| 前收市價 | 313.14 |
| 開市 | 329.00 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 314.00 - 335.08 |
| 52 週波幅 | 299.01 - 430.00 |
| 成交量 | |
| 平均成交量 | 6,761 |
| 市值 | 261.046B |
| Beta 值 (5 年，每月) | 0.28 |
| 市盈率 (最近 12 個月) | 18.12 |
| 每股盈利 (最近 12 個月) | 18.27 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 9.97 (3.02%) |
| 除息日 | 2022年3月17日 |
| 1 年預測目標價 | 無 |
- Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
The European Commission approved Roche Holding AG's (OTC: RHHBY) Vabysmo (faricimab) for neovascular or 'wet' age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME). These retinal conditions affect more than 40 million people globally. Vabysmo is the only injectable eye medicine approved in Europe, with phase 3 studies supporting treatment at intervals of up to four months for people living with nAMD and DME. Also Read: WHO Recommends Against Roche, GSK
- AASTOCKS
歌禮製藥-B(01672.HK)附屬年底終止羅氏製藥「派羅欣」內地推廣服務
歌禮製藥-B(01672.HK)公布，公司全資附屬歌禮生物與羅氏製藥中國完成補充協議的簽署。根據該協議，歌禮生物將於今年12月31日起，終止向羅氏製藥中國提供「派羅欣」(一種治療乙型和丙型肝炎的聚乙二醇干擾素)的推廣服務。 集團指，在經過長期成功的合作後，基於羅氏製藥中國對「派羅欣」在中國大陸地區市場策略的調整，歌禮生物與羅氏製藥中國已達成一致，自今年底起雙方不再繼續「派羅欣」在中國大陸地區市場的推廣合作關係。羅氏製藥中國亦不會再尋求其他合作方，也不會在中國大陸地區開展「派羅欣」的商業推廣。(ek/u)~ 阿思達克財經新聞 網址: www.aastocks.com
- Benzinga
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech
After penning a deal with Orion in May for a non-opioid pain drug, Jemincare is back at the licensing deal table, inking a development and sales deal with Roche Holdings AG's (OTC: RHHBY) Genentech unit for a prostate cancer drug. In return, Genentech will get a worldwide license to develop the program, known as JMKX002992, and bring it to market. JMKX002992 is a novel oral degrader of the androgen receptor, a confirmed disease driver in prostate cancer. The company says JMKX002992 has the poten
